Celltrion Healthcare Competitors and Similar CompaniesClear all

Celltrion Healthcare's competitors and similar companies include CureVac, Candel Therapeutics and OBI Pharma.

	Celltrion Healthcare Celltrion Healthcare is a biopharmaceutical company specializing in oncology, influenza, psoriasis, and arthritis.,	CureVac CureVac is a biotechnology company offering messenger RNA (mRNA) technology.	Candel Therapeutics Candel Therapeutics (formerly known as Advantagene) is a biopharmaceutical company developing cancer immunotherapies.	OBI Pharma OBI Pharma (台灣浩鼎) is a bio-pharma company focused on cancer therapeutics.
Founding Date	Founding Date 2002	Founding Date 2000	Founding Date 1999	Founding Date 2002
Type	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Incheon, KR HQ	Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US	Locations Needham, US HQ	Locations TW HQ San Diego, US
Employees	Employees 6301% increase	Employees 999	Employees 50	Employees 124
Valuation ($)	Valuation ($) N/A	Valuation ($) 648.3 m	Valuation ($) 176.8 m	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) ₩2t (FY, 2022)	Revenue (est.) €53.8m (FY, 2023)	Revenue (est.) N/A	Revenue (est.) NT$41.5m (FY, 2023)
Cost of goods	Cost of goods ₩1.4t (FY, 2022)	Cost of goods €64.3m (FY, 2023)	Cost of goods N/A	Cost of goods NT$115m (FY, 2023)
Gross profit	Gross profit ₩664.7b (FY, 2022)	Gross profit (€2.6m) (FY, 2023)	Gross profit N/A	Gross profit (NT$63.8m) (FY, 2023)
Net income	Net income ₩147.2b (FY, 2022)	Net income (€260.2m) (FY, 2023)	Net income ($55.2m) (FY, 2024)	Net income (NT$1.3b) (FY, 2023)
Funding
Total funding raised	Total funding raised N/A	Total funding raised $ 1.1b	Total funding raised $ 64.6m	Total funding raised N/A